Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma (Q92610920)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

title

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Manoela Tiago

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Claudia Capparelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Dan A Erkes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Timothy J Purwin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Shea A Heilman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Adam C Berger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Michael A Davies

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Andrew E Aplin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

publication date

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

30 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

volume

122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

page(s)

789-800

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

30 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Risk of cumulative toxicity after complete melanoma response with pembrolizumab.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Phenotype switching in melanoma: implications for progression and therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

The mechanisms behind the therapeutic activity of BET bromodomain inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

TCPA: a resource for cancer functional proteomics data

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Selective inhibition of BET bromodomains

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

BET inhibitors: a novel epigenetic approach

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-019-0724-Y

7 January 2021

10.1038/S41416-019-0724-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31932756%20AND%20SRC:MED&resulttype=core&format=json